Multicancer Early Detection (MCED) Blood Tests: Understanding the Latest Clinical Trial Results

The quest for a “universal” blood test capable of detecting multiple cancers at their earliest, most treatable stages remains one of the most ambitious goals in modern oncology. Recently, the results of the landmark NHS-Galleri trial—a large-scale randomized study evaluating a multicancer early detection (MCED) test—have sparked significant discussion regarding the current role of liquid biopsies in population-level screening.

What is an MCED Test?

Multicancer early detection tests, such as the Galleri test, are designed to analyze cell-free DNA (cfDNA) circulating in the bloodstream. These tests look for specific methylation patterns—chemical modifications to DNA that act as a “fingerprint” for cancerous cells. The goal is to identify the presence of malignancy and, crucially, predict the tissue of origin before a patient develops physical symptoms.

Key Takeaways from the NHS-Galleri Trial

The NHS-Galleri trial, which enrolled over 140,000 asymptomatic participants aged 50 to 77, sought to determine if annual MCED screening could reduce the number of late-stage (stage III/IV) cancer diagnoses. The findings, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, provided a nuanced look at the technology’s current capabilities:

• Primary Endpoint Not Met: The study did not demonstrate a statistically significant reduction in combined stage III and stage IV diagnoses for the 12 prespecified cancer types evaluated.
• Reduction in Stage IV Disease: Secondary analysis indicated a 14% reduction in stage IV cancers after three years of annual screening, suggesting a potential benefit that may strengthen with longer follow-up.
• Increased Early Detection: The trial observed a 16% increase in stage I and stage II cancer diagnoses among the intervention group, highlighting the test’s ability to identify tumors earlier than standard care alone.
• High Specificity: The test demonstrated high specificity (99.55%), meaning the rate of false positives—which can lead to unnecessary anxiety and invasive diagnostic procedures—remained low.

The Clinical Perspective: Why Current Guidelines Remain Unchanged

While these results offer a glimpse into the future of cancer screening, medical experts emphasize that we are not yet at a point where MCED tests should replace or augment established screening protocols for the general population.

According to Dr. Julie R. Gralow, Chief Medical Officer and Executive Vice President of ASCO, the bar for adopting new screening technologies is exceptionally high. Current standard-of-care screenings—such as mammograms, colonoscopies, and lung cancer screenings—are recommended because they have been proven to reduce cancer-specific mortality. Because the NHS-Galleri trial did not meet its primary endpoint of reducing late-stage diagnoses, clinical guidelines do not yet recommend the routine use of these assays for early cancer detection in asymptomatic individuals.

Frequently Asked Questions (FAQ)

Are MCED tests available for the general public?

While some tests are marketed for clinical use, they are generally not recommended by major medical organizations for routine, population-based screening. They are often used in specific clinical contexts or research settings.

Can this blood test replace a colonoscopy or mammogram?

No. Standard screening tests for colorectal, breast, cervical, and lung cancers are highly effective and remain the gold standard. MCED tests are currently viewed as a potential future supplement rather than a replacement for established, evidence-based screenings.

What does a positive result mean?

A positive result from an MCED test indicates the presence of a “cancer signal.” However, it does not confirm a cancer diagnosis. Any positive finding requires follow-up diagnostic testing—such as imaging (CT or MRI) or biopsies—to confirm the location and type of cancer.

Future Outlook

The scientific community continues to study the long-term impact of MCED testing. Ongoing research, including studies like the REACH study in the United States, aims to determine if these tests can eventually improve survival rates. As technology improves and more longitudinal data becomes available, the integration of liquid biopsies into routine healthcare may become a reality. For now, however, patients should continue to prioritize established, guideline-recommended cancer screenings and discuss any personal risk factors or concerns with their primary care physician or oncologist.

Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician with any questions regarding a medical condition.